Among the 24,922 non-Sq NSCLC harboring KRAS alterations, the most common co-alterations included loss-of-function alterations in TP53, STK11, KEAP1, and CDKN2A/B (Fig. 2a, Supplementary Data 4). This evidence concerns the gene KRAS and non-small cell lung carcinoma.